Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan hydrochloride liposomal - Luye Pharma Group

Next Previous
Drug Profile

Irinotecan hydrochloride liposomal - Luye Pharma Group

Alternative Names: Irinotecan hydrochloride liposome injection - Luye Pharma; LY 01610

Latest Information Update: 03 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luye Pharma Group
  • Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase II Colorectal cancer; Oesophageal cancer; Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued Rectal cancer

Most Recent Events

  • 28 May 2024 Ba Yi, Peking Union Medical College Hospital in collaboration with CSPC Ouyi Pharmaceutical plans a phase II trial for Biliary cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/unresectable) in China (IV, Infusion) (NCT06430827)
  • 04 Mar 2024 Luye Pharma completes a phase-II clinical trials in Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (IV) prior to March 2024(NCT04381910)
  • 03 Mar 2024 Phase-III clinical trials in Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT06128837)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top